Lonza Group AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lonza Group AG
The Ireland-headquartered firm will advance the candidate into US and EU narcolepsy studies as part of its pipeline diversification project as portfolio products are set to lose their patent exclusivity.
The vice-chairman of Singapore-based Prestige Group talks to Scrip about the biopharma's strategies in Asia and elsewhere, as it focuses on vaccines for COVID-19 and other diseases, along with novel antibody therapeutics in oncology and biosimilars.
Following Shanghai, China’s third-largest city Guangzhou is now on high alert as Omicron cases spread, while pharma and biotech face severe production and supply chain disruptions.
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.